On Friday, Amicus Therapeutics Inc (NASDAQ: FOLD) opened lower -2.25% from the last session, before settling in for the closing price of $6.21. Price fluctuations for FOLD have ranged from $5.81 to $12.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 23.72% over the last five years. Company’s average yearly earnings per share was noted 51.94% at the time writing. With a float of $297.28 million, this company’s outstanding shares have now reached $307.92 million.
The firm has a total of 499 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.99%, operating margin of 7.11%, and the pretax margin is -0.59%.
Amicus Therapeutics Inc (FOLD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Amicus Therapeutics Inc is 3.46%, while institutional ownership is 99.75%. The most recent insider transaction that took place on Feb 19 ’25, was worth 4,000. In this transaction President and CEO of this company sold 400 shares at a rate of $10.00, taking the stock ownership to the 1,150,657 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Director proposed sale 400 for $9.85, making the entire transaction worth $3,940.
Amicus Therapeutics Inc (FOLD) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 51.94% per share during the next fiscal year.
Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators
Check out the current performance indicators for Amicus Therapeutics Inc (FOLD). In the past quarter, the stock posted a quick ratio of 2.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.44. Likewise, its price to free cash flow for the trailing twelve months is 1160.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach 0.26 in one year’s time.
Technical Analysis of Amicus Therapeutics Inc (FOLD)
Analysing the last 5-days average volume posted by the [Amicus Therapeutics Inc, FOLD], we can find that recorded value of 4.61 million was better than the volume posted last year of 3.43 million. As of the previous 9 days, the stock’s Stochastic %D was 27.17%. Additionally, its Average True Range was 0.29.
During the past 100 days, Amicus Therapeutics Inc’s (FOLD) raw stochastic average was set at 6.21%, which indicates a significant decrease from 30.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.06% in the past 14 days, which was higher than the 43.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.01, while its 200-day Moving Average is $9.44. Now, the first resistance to watch is $6.17. This is followed by the second major resistance level at $6.26. The third major resistance level sits at $6.33. If the price goes on to break the first support level at $6.00, it is likely to go to the next support level at $5.93. Now, if the price goes above the second support level, the third support stands at $5.84.
Amicus Therapeutics Inc (NASDAQ: FOLD) Key Stats
There are currently 307,931K shares outstanding in the company with a market cap of 1.87 billion. Presently, the company’s annual sales total 528,300 K according to its annual income of -56,110 K. Last quarter, the company’s sales amounted to 125,250 K and its income totaled -21,690 K.
